Tagged with innovation,

Austria Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative products. Globally, UCB registered nine percent growth for the first nine months of 2017. How would you describe the contribution…

Lithuania Marijus Valatka, general manager Lithuania, Latvia and Estonia at Novo Nordisk, explains the current challenges and areas for improvement in diabetes treatment in Lithuania and stresses the company’s commitment to not only bring medicines to the market but also enhance the quality of treatment fort diabetes and other serious chronic…

India Kanchana TK, director general of the Organisation of Pharmaceutical Producers of India (OPPI), the association which represents the interests of research-based pharmaceutical companies in India, discusses regulatory reform and how OPPI is helping to shape the Indian healthcare system. Please introduce yourself to our international readers and your journey to…

Canada Michael Rudnicki, chair of the Regenerative Medicine Alliance of Canada (RMAC) discusses the mandate of the newly established organization, the exciting potential of regenerative medicine, and Canada’s competitive edge in this cutting-edge field. Michael, could you share the mandate and mission of the newly established Regenerative Medicine Alliance of Canada…

Poland Denis Vujičić, managing director of MSD Poland, discusses his overriding mission to give Polish patients greater access to breakthrough therapies and highlights the affiliate’s extensive R&D capabilities that entail both domestic and global operations. Furthermore, he highlights the important steps that MSD is undertaking to strengthen its position as the…

Switzerland In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new CAR-T cell therapy, Kymriah, and the issues around pricing for this revolutionary treatment.   * Please note that this interview was…

Serbia Bojan Trkulja, managing director of INOVIA, Serbia’s innovative drug manufacturers association, underlines the importance of cooperation not only between his members but also between all the key stakeholders of the Serbian healthcare and life science industry, concluding that the time for investment in Serbia is now and that the country…

Switzerland Oliver Rinner, CEO and founder of Biognosys, provides a fascinating account of the company’s unique business model and explains how its technical research into proteomics and cell expression is likely to be even more successful despite continuous technological developments. Biognosys – a proteomics focused company – was initially founded as…

Brazil Bruno Costa Gabriel, managing director of Janssen Brazil, provides insights into the transformative market approach successfully implemented by this leading company in Brazil and his main priorities to further leverage the great potential of Janssen’s innovation and impact an ever-increasing number of Brazilian patients.   You display a truly international…

Brazil Pius Hornstein, MSc, PhD, country chair Sanofi Brazil and general manager Pharma, shares his positive outlook on the Brazilian pharma market over the next few years and details Sanofi’s strategy in Brazil; a ‘must-win’ market for the company. Unsatisfied with being just the top-ranked multinational pharma company in Brazil, he…

Canada Quebec’s Deputy Premier and Minister of Economy, Science and Innovation Dominique Anglade, who is also the Minister responsible for the Digital Strategy, shares the strategic significance of her portfolios to Quebec’s national development, the CAD 205 million Quebec is investing into the life sciences sectors over the next five years,…

Japan Yuzo Toda, chairman of the Forum for Innovative Regenerative Medicine (FIRM) in Japan, discusses how the organization acts as a translational bridge between academia and industry, how the paradigm of regenerative medicine differs from that of traditional pharmaceuticals, and why Japan has taken the lead in this exciting new field.…